Article
No impact of resistance-associated substitutions on the efficacy of sofosbuvir, velpatasvir, and voxilaprevir for 12 weeks in HCV DAA-experienced patients.
Journal of hepatology - 1 Dec 2018
Sarrazin Christoph, Cooper Curtis L, Manns Michael P, Reddy K Rajender, Kowdley Kris V, Roberts Stuart K, Dvory-Sobol Hadas, Svarovskia Evguenia, Martin Ross, Camus Gregory, Doehle Brian P, Stamm Luisa M, Hyland Robert H, Brainard Diana M, Mo Hongmei, Gordon Stuart C, Bourliere Marc, Zeuzem Stefan, Flamm Steven L
Abstract excerpt
BACKGROUND & AIMS: In phase III studies, the fixed dose combination of sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) administered for 12 weeks led to a sustained virologic response at 12 weeks (SVR12) in 96% of NS5A inhibitor-experienced patients, and an SVR12 rate of 98% in DAA-experienced patients who had not previously received an NS5A inhibitor. Herein, we evaluate the relationship between the presence of...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.